The company's diverse pipeline of Treg-modulating candidates seeks to restore immune balance by targeting inflammation, a common and critical factor in the progression of numerous neurodegenerative diseases (NDDs) and autoimmune diseases. Coya aims to treat 1.7 million patients across the U.S., with a total addressable market exceeding $7 billion. Moreover, Coya recently reported encouraging results from its proof-of-concept study in ALS patients. COYA 302 effectively slowed disease progression, ....
10 May 2023
Coya Therapeutics (NASDAQ: COYA)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Coya Therapeutics (NASDAQ: COYA)
The company's diverse pipeline of Treg-modulating candidates seeks to restore immune balance by targeting inflammation, a common and critical factor in the progression of numerous neurodegenerative diseases (NDDs) and autoimmune diseases. Coya aims to treat 1.7 million patients across the U.S., with a total addressable market exceeding $7 billion. Moreover, Coya recently reported encouraging results from its proof-of-concept study in ALS patients. COYA 302 effectively slowed disease progression, ....